“…There is a dose–response relationship between the use of mannitol and the incidence and severity of AKI, with a cut-off of the daily dose at 1.34 g/kg body weight [ 73 ]. Interestingly, the combined therapy of ICH with mannitol and HTS did not increase the risk of AKI more than HTS alone, however several authors suggested to use HTS, demonstrating its superiority over mannitol [ 13 , 14 , 16 , 18 , 74 ]. In conclusion, it can be postulated that an increase in plasma hyperosmolality per se, as well as the use of osmotically active medications, may impair renal function, and that maintaining adequate renal perfusion may reduce the risk of AKI.…”